SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
The non- clinical study was conducted at The Chaim Sheba Medical Center in Israel
Tel-Aviv, Dec. 07, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq:SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced positive results from its study of SCI-210 on Status Epilepticus (“SE”), conducted at The Sheba Fund for Health Services and Research at Chaim Sheba Medical Center, which reaffirm the potential of its proprietary combination products to have a positive effect while minimizing adverse side effects. The Company’s proprietary SCI-210 platform combines Palmitoylethanolamide (“PEA”) with Cannabidiol (“CBD”).
Related news for (SPRC)
- Real Assets, Real Shifts: VENU Breaks Ground on New Real Estate Model; Drones, Silicon Carbide, and Quantum Rails Redraw Market Lines
- MoBot alert highlights: NASDAQ: SGLY, NASDAQ: SPRC, NASDAQ: BENF, NASDAQ: EPOW, NASDAQ: VIVK (09/30/25 06:00 AM)
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/30/25 05:00 AM
- Breaking News: MoBot’s Latest Update as of 09/30/25 04:00 AM
- SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer